Blockchain Registration Transaction Record

Revolutionizing Colorectal Cancer Screening Market

Mainz Biomed NV and Exact Sciences Corp. are transforming the colorectal cancer screening market with their at-home tests, ColoAlert and Cologuard. Learn how these non-invasive tests offer better early detection and could impact treatment and prevention.

Colorectal cancer is a deadly disease, but with the launch of at-home screening tests like ColoAlert and Cologuard, early detection and prevention could be dramatically improved. Mainz Biomed's potential for growth, especially with the anticipated FDA approval for selling ColoAlert in the U.S., makes it a story worth following. The impact of these innovative tests could lead to better outcomes for millions of people at risk of colorectal cancer.